Solitary lymph node metastasis is a distinct subset of colon cancer associated with good survival: a retrospective study of surveillance, epidemiology, and end-results population-based data

BMC Cancer

Qingguo Li¹  Yuwei Wang¹  Guoxiang Cai¹  Dawei Li¹  Sanjun Cai¹ 

[1] Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong’an Road, Shanghai 20032, China

关键词: Survival analysis;    Surgery;    Lymph node metastasis;    Colon Cancer;   

Others  :  858790
DOI  :  10.1186/1471-2407-14-368

 received in 2014-01-15, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

Colon cancer with lymph node metastases has been considered as advanced stage and to have poor survival. We postulated that patients with solitary lymph node metastasis are a distinct subset with better colon cancer-specific survival than those with multiple lymph node metastases.

Methods

In this retrospective study, we searched Surveillance, Epidemiology, and End-Results (SEER) population-based data and identified 86,674 patients who had been diagnosed with colon cancer without distant metastases and with less than three metastatic nodes between 1991 and 2005. We divided lymph node status into three subgroups: pN0, pN1a, and pN1b and obtained 5-year colon cancer-specific survival for each pT stage. We used Kaplan–Meier and multivariate Cox regression models to assess correlations between risk factors and survival outcomes.

Results

Analysis of SEER data confirmed that patients with solitary lymph node metastases had better 5-year cancer-specific survival than pN1b according to both univariate and multivariate analysis. This finding was confirmed by further analyses in five pT subgroups. Cancer-specific survival of patients with pT1-2N1a was comparable to that of those with pIIA but higher than those with pIIB. In addition, survival of patients with pT3-4aN1a was better than those with pIIC.

Conclusion

Colon cancer patients with solitary lymph node metastasis are a distinct subset with a favorable prognosis; full consideration should be given to this in clinical practice.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
• [2]Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Matsuda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK, Asia Pacific Working Group on Colorectal Cancer: Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008, 57(8):1166-1176.
• [3]Byeon JS, Yang SK, Kim TI, Kim WH, Lau JY, Leung WK, Fujita R, Makharia GK, Abdullah M, Hilmi I, Sollano J, Yeoh KG, Wu DC, Chen MH, Kongkam P, Sung JJ, Asia Pacific Working Group for Colorectal Cancer: Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey. Gastrointest Endosc 2007, 65(7):1015-1022.
• [4]Lei T, Chen WQ, Zhang SW, Lei TH, Ying Q, He ZY, Wang XH: Prevalence trend of colorectal cancer in 10 cities and counties in China from 1988 to 2002. Zhonghua Zhong Liu Za Zhi 2009, 31(6):428-433.
• [5]Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010, 28(2):264-271.
• [6]Hong KD, Lee SI, Moon HY: Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer. J Surg Oncol 2011, 103(5):406-410.
• [7]Suzuki O, Sekishita Y, Shiono T, Ono K, Fujimori M, Kondo S: Number of lymph node metastases is better predictor of prognosis than level of lymph node metastasis in patients with node-positive colon cancer. J Am Coll Surg 2006, 202(5):732-736.
• [8]Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M: Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol 2012, 61(2):237-242.
• [9]Tu SL, Ye ZY, Deng GL, Zhao ZS, Dong QJ, Zheng BA, Ding LP, Cao HF: Rule of lymph node metastasis in colorectal cancer and its affecting factors. Zhonghua Wei Chang Wai Ke Za Zhi 2007, 10(3):257-260.
• [10]Soni M, Wiese D, Korant A, Sirop S, Chakravarty B, Gayar A, Bilchik A, Beutler T, Ratz D, Saha S: Comparison of nodal positivity between SLNM vs conventional surgery in colon cancer patients with <12 and >/=12 lymph nodes harvested. Am J Surg 2011, 202(2):207-213.
• [11]O’Riordan JM, Rowley S, Murphy JO, Ravi N, Byrne PJ, Reynolds JV: Impact of solitary involved lymph node on outcome in localized cancer of the esophagus and esophagogastric junction. J Gastrointest Surg 2007, 11(4):493-499.
• [12]Kunisaki C, Makino H, Kimura J, Oshima T, Fujii S, Takagawa R, Kosaka T, Ono H, Akiyama H, Endo I: Therapeutic strategy for esophageal cancer based on solitary lymph node metastasis. Hepatogastroenterol 2011, 58(110–111):1561-1565.
• [13]Bardia A, Greeno E, Miller R, Alberts S, Dozois E, Haddock M, Limburg P: Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? Colorectal Dis 2010, 12(4):312-315.
• [14]Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Hölscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, Lerut T, DeMeester TR: Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008, 248(6):979-985.
• [15]Bilimoria KY, Bentrem DJ, Stewart AK, Talamonti MS, Winchester DP, Russell TR, Ko CY: Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst 2008, 100(18):1310-1317.
• [16]Vather R, Sammour T, Kahokehr A, Connolly AB, Hill AG: Lymph node evaluation and long-term survival in stage II and stage III colon cancer: a national study. Ann Surg Oncol 2009, 16(3):585-593.
• [17]Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003, 21(15):2912-2919.
• [18]Prandi M, Lionetto R, Bini A, Francioni G, Accarpio G, Anfossi A, Ballario E, Becchi G, Bonilauri S, Carobbi A, Cavaliere P, Garcea D, Giuliani L, Morziani E, Mosca F, Mussa A, Pasqualini M, Poddie D, Tonetti F, Zardo L, Rosso R: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002, 235(4):458-463.
• [19]Saha S, Sehgal R, Patel M, Doan K, Dan A, Bilchik A, Beutler T, Wiese D, Bassily N, Yee C: A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg 2006, 191(3):305-310.
• [20]Chau I, Cunningham D: Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev 2002, 28(5):223-236.
• [21]O’Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96(19):1420-1425.
• [22]Rottoli M, Stocchi L, Dietz DW: T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol 2012, 19(8):2500-2505.
• [23]Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322(6):352-358.
• [24]Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22(10):1797-1806.
• [25]Taal BG, Van Tinteren H, Zoetmulder FA: Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001, 85(10):1437-1443.
• [26]Garcia-Granero E, Frasson M, Pous S, Cervantes A: T4a and t4b colorectal cancer: what does this mean nowadays? Dis Colon Rectum 2012, 55(11):e367.